KENLIVABY Trademark

Trademark Overview

On Wednesday, July 14, 2021, a trademark application was filed for KENLIVABY with the United States Patent and Trademark Office. The USPTO has given the KENLIVABY trademark a serial number of 90827345. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Thursday, February 29, 2024. This trademark is owned by Idorsia Pharmaceuticals Ltd. The KENLIVABY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment of Fabry disease and symptoms and sequelae of Fabry disease, and for the treatment of glycolipid storage disorders
kenlivaby

General Information

Serial Number90827345
Word MarkKENLIVABY
Filing DateWednesday, July 14, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateThursday, February 29, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 19, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment of Fabry disease and symptoms and sequelae of Fabry disease, and for the treatment of glycolipid storage disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, June 15, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameIdorsia Pharmaceuticals Ltd
Party Type20 - Owner at Publication
Legal Entity Type09 - Joint Stock Company
AddressAllschwil 4123
CH
Party NameIdorsia Pharmaceuticals Ltd
Party Type10 - Original Applicant
Legal Entity Type09 - Joint Stock Company
AddressAllschwil 4123
CH

Trademark Events

Event DateEvent Description
Friday, March 1, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 29, 2024SOU EXTENSION 3 GRANTED
Thursday, February 29, 2024SOU EXTENSION 3 FILED
Thursday, February 29, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, August 23, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 21, 2023SOU EXTENSION 2 GRANTED
Monday, August 21, 2023SOU EXTENSION 2 FILED
Monday, August 21, 2023SOU TEAS EXTENSION RECEIVED
Thursday, March 2, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 28, 2023SOU EXTENSION 1 GRANTED
Tuesday, February 28, 2023SOU EXTENSION 1 FILED
Tuesday, February 28, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, September 13, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 19, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 19, 2022PUBLISHED FOR OPPOSITION
Wednesday, June 29, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 15, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 15, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, June 15, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, June 15, 2022EXAMINERS AMENDMENT E-MAILED
Wednesday, June 15, 2022EXAMINERS AMENDMENT -WRITTEN
Monday, April 11, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 11, 2022NON-FINAL ACTION E-MAILED
Monday, April 11, 2022NON-FINAL ACTION WRITTEN
Monday, April 4, 2022ASSIGNED TO EXAMINER
Friday, September 17, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, July 17, 2021NEW APPLICATION ENTERED

Related Keywords

kenlivaby fabry treatment disease glycolipid storage disorders sequelae symptoms preparations pharmaceutical